Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.

Autor: Jørgensen NG; Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark., Ahmad SM; Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark., Abildgaard N; Department of Hematology, University Hospital Odense, Odense, Denmark., Straten PT; Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark., Svane IM; Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark;; Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark., Andersen MH; Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark., Knudsen LM; Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark.
Jazyk: angličtina
Zdroj: Stem cell investigation [Stem Cell Investig] 2016 Dec 23; Vol. 3, pp. 95. Date of Electronic Publication: 2016 Dec 23 (Print Publication: 2016).
DOI: 10.21037/sci.2016.11.09
Abstrakt: The B-cell lymphoma-2 (Bcl-2) family of proteins play a crucial role in multiple myeloma (MM), contributing to lacking apoptosis which is a hallmark of the disease. This makes the Bcl-2 proteins interesting targets for therapeutic peptide vaccination. We report a phase I trial of therapeutic vaccination with peptides from the proteins Bcl-2, Bcl-X L and Mcl-1 in patients with relapsed MM. Vaccines were given concomitant with bortezomib. Out of 7 enrolled patients, 4 received the full course of 8 vaccinations. The remaining 3 patients received fewer vaccinations due to progression, clinical decision of lacking effect and development of hypercalcemia, respectively. There were no signs of toxicity other than what was to be expected from bortezomib. Immune responses to the peptides were seen in all 6 patients receiving more than 2 vaccinations. Three patients had increased immune responses after vaccination. Vaccination against Bcl-2 was well tolerated and was able to induce immune responses in patients with relapsed MM.
Competing Interests: The authors have no conflicts of interest to declare.
Databáze: MEDLINE
Externí odkaz: